Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Riboflavin tetrabutyrate is a synthetic ester derivative of vitamin B2 (riboflavin), in which the four hydroxyl groups of the ribityl side chain are esterified with butyric acid. It is used primarily as an ingredient in multivitamin complexes, especially in Japan, for relief of symptoms such as stomatitis, glossitis, perleche, cheilitis, rough skin, acne, dermatitis, eczema, rash and sores[1][3]. In vitro studies have shown that it can inhibit ADP-induced and arachidonic acid-induced platelet aggregation at certain concentrations[1]. Its mechanism of action is presumed to be similar to that of other forms of riboflavin—serving as a precursor for flavocoenzymes involved in cellular redox reactions—but may also include additional effects due to its esterified form. It is not widely marketed under specific brand names and appears mainly as a research chemical or supplement ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on riboflavin tetrabutyrate.